University of Bristol SEDGLEY UKRI Innovation Fellowships: BBSRC Flexible Talent Mobility Accounts
Lead Research Organisation:
University of Bristol
Department Name: Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Kathleen Sedgley (Principal Investigator) |
Publications
Dawson WM
(2023)
Differential sensing with arrays of de novo designed peptide assemblies.
in Nature communications
| Title | Bristol BioDesign Institute Illustration |
| Description | An illustration of the scale and breadth of expertise encompassed by the BioDesign community at the University of Bristol. This has been used in many contexts, including on a physical 'Totem Pole' adjacent to the BrisSynBio and Bristol BioDesign Institute hub. |
| Type Of Art | Artwork |
| Year Produced | 2018 |
| Impact | None yet |
| URL | https://www.google.com/maps/place/Bristol+BioDesign+Institute/@51.4591484,-2.6012334,15z/data=!4m5!3... |
| Description | The early career secondments that this award have supported have contributed considerably to the incorporation and growth of four Bristol-based synthetic biology start up companies. The SMEs that hosted these placements make a significant contribution to the local economy, collectively raising over £10 and creating more than 30 jobs to date. |
| First Year Of Impact | 2018 |
| Sector | Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |
| Description | BrisSynBio SynbiCITE 4-day MBA |
| Geographic Reach | Europe |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Business acumen: The award funded the 2018 BrisSynBio and SynbiCITE 4-Day MBA, which is an interactive programme designed to provide the skills required to establish, build and manage a biotech or life sciences company based on synthetic biology. 26 early career researchers travelled to Bristol from around the UK and one participant travelled from Spain. Nine synthetic biology business plans were developed and pitched at the public BrisSynBio Connect event, which was attended by academics, indutrialists and investors. |
| Description | BrisEngBio: From Synthetic to Engineering Biology at Bristol |
| Amount | £1,517,913 (GBP) |
| Funding ID | BB/W013959/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2022 |
| End | 01/2024 |
| Description | Bristol BioDesign Institute - BrisSynBio - Flexible Talent Mobility Account |
| Amount | £270,000 (GBP) |
| Funding ID | BB/S507891/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 03/2021 |
| Description | Cytoseek |
| Organisation | CytoSeek |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provided funding and secondee |
| Collaborator Contribution | Provided secondment opportunity |
| Impact | None yet |
| Start Year | 2018 |
| Description | Rosa Biotech (2019) |
| Organisation | Rosa Biotech Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We have included Rosa in events and networking activities, and have offerd the opportuntiy to host secondments and contribute to training ECRs in synthetic biology |
| Collaborator Contribution | Rosa has hosted subsequent innovation secondments |
| Impact | NA |
| Start Year | 2019 |
| Description | Zentraxa |
| Organisation | Zentraxa Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provided funding and secondee |
| Collaborator Contribution | Provided secondment opportunity |
| Impact | None yet |
| Start Year | 2018 |
| Company Name | IMOPHORON LIMITED |
| Description | An innovative vaccine technology start-up |
| Year Established | 2017 |
| Impact | None yet |
| Company Name | CYTOSEEK LIMITED |
| Description | Next Generation of Cell Therapies CytoSeek is developing its Artificial Membrane Binding Protein (AMBP) technology to enhance cell therapies for use in tumour therapies. AMBPs, which bind to virtually all cell types, have a modular design that allows rapid prototyping to deliver new functionalities. Currently, we are developing AMBPs that can provide homing, immunomodulation, and/or hypoxia resistance functionality. |
| Year Established | 2017 |
| Impact | None yet |
| Website | https://www.cytoseek.uk/ |
| Company Name | ZENTRAXA LIMITED |
| Description | Precision engineering bespoke peptide biomaterials |
| Year Established | 2017 |
| Impact | Applications in medical and industrial adhesives and personal care |
| Website | https://zentraxa.com/ |
| Company Name | ROSA BIOTECH LIMITED |
| Description | Rosa Biotech is redefining biosensing. We are enabling previously intractable challenges in early disease diagnosis and industrial biotechnology to be addressed accurately and at scale. Rosa's patent-pending technology builds upon and extends the pioneering protein design work of Prof. Dek Woolfson and his team at the University of Bristol's Synthetic Biology Research Centre, BrisSynBio. By combining this with advanced machine-learning techniques, Rosa offers a powerful platform capable of being trained to address numerous complex biosensing problems |
| Year Established | 2019 |
| Impact | NA |
| Website | https://www.rosabio.tech/ |